title: Immunosuppression in IgA nephropathy: how certain are we?
abstract: The optimal role of immunosuppressive therapy in the treatment of IgA nephropathy is controversial. Results of a recently completed randomized controlled trial provide strong support for comprehensive supportive care rather than immunosuppressive therapy in patients at high risk for progression.
authors.affiliation: Division of Nephrology and Clinical Immunology, RWTH University of Aachen, Aachen, Germany. Electronic address: Juergen.floege@rwth-aachen.de.
authors.forename: Jürgen
authors.initials: J
authors.lastname: Floege
authors.affiliation: Division of Nephrology and Clinical Immunology, RWTH University of Aachen, Aachen, Germany.
authors.forename: Thomas
authors.initials: T
authors.lastname: Rauen
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use; D005919:Glomerular Filtration Rate; D005922:Glomerulonephritis, IGA / Q000188:drug therapy* / Q000503:physiopathology / Q000628:therapy; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D011507:Proteinuria / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic; D012084:Renin-Angiotensin System / Q000187:drug effects
chemical_list: D000959:Antihypertensive Agents; D007166:Immunosuppressive Agents